AstraZeneca is voluntarily recalling close to 150,000 Tudorza Pressair inhalers because of flaws in the device’s delivery system.
AstraZeneca had to recall inhalers in Denmark last year because some of them may have been empty. Now it’s doing the same in the US where some of its Tudorza Pressair inhalers may be defective.
According to the most recent FDA Enforcement Report, the UK company is voluntarily recalling nearly 150,000 Tudorza Pressair inhalers manufactured in Spain because the delivery system may be improperly set and may not provide the full 60 doses of aclidinium bromide inhalation powder they are designed to deliver.
AstraZeneca bought both the Tudorza Pressair and Daliresp respiratory meds last year from what is now Allergan for $600 million and royalties. AstraZeneca has bought a number of respiratory products in the last few years to boost its place in that category as it faced losing patent protection on blockbuster asthma med Symbicort. In 2014 it spent more than $2.2 billion for the respiratory meds of Spain’s Almirall.